Heritage Investors Management Corp raised its position in shares of Pfizer, Inc. (NYSE:PFE) by 2.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 417,267 shares of the biopharmaceutical company’s stock after acquiring an additional 10,719 shares during the quarter. Heritage Investors Management Corp’s holdings in Pfizer were worth $14,016,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Sphera Funds Management LTD. acquired a new position in shares of Pfizer during the first quarter valued at approximately $13,342,000. Searle & CO. raised its holdings in shares of Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after acquiring an additional 38,500 shares during the last quarter. E&G Advisors LP raised its holdings in shares of Pfizer by 6.8% during the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock valued at $2,130,000 after acquiring an additional 3,940 shares during the last quarter. Insight 2811 Inc. raised its holdings in shares of Pfizer by 3.7% during the first quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 329 shares during the last quarter. Finally, Prentiss Smith & Co. Inc. raised its holdings in shares of Pfizer by 1.7% during the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 250 shares during the last quarter. 69.00% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.320% on Monday, reaching $35.845. The company had a trading volume of 4,500,161 shares. The firm has a 50-day moving average price of $33.78 and a 200 day moving average price of $33.53. The firm has a market capitalization of $213.18 billion, a price-to-earnings ratio of 26.222 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.21.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 EPS. Equities research analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.
In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ian C. Read sold 197,168 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the sale, the chief executive officer now owns 580,318 shares of the company’s stock, valued at $19,730,812. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Insiders own 0.06% of the company’s stock.
A number of equities analysts have commented on the company. Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Jefferies Group LLC set a $37.00 target price on Pfizer and gave the company a “neutral” rating in a report on Monday, September 18th. BMO Capital Markets reissued a “buy” rating and set a $37.00 target price on shares of Pfizer in a report on Thursday, September 14th. Finally, Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target for the company. in a report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $38.04.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.